This study is looking at how targeted therapies affect radioactive iodine (RAI) uptake in patients with metastatic differentiated thyroid cancer (DTC), including papillary thyroid cancer (PTC). These cancers often have specific genetic changes like NTRK-fusion, RET-fusion, ALK-fusion, or BRAF V600 mutation. You might be eligible if you have one of these genetic changes and are already receiving targeted therapy, either commercially or through another clinical trial. The study will observe if your tumor's ability to absorb RAI increases after about four weeks of targeted therapy. Researchers will measure this change with a whole body scan. The goal is to understand if these targeted treatments can make RAI more effective for shrinking tumors.

Study design

This is an observational study with a planned enrollment of 32 patients. It is not specified if it is randomized or blinded.

What's involved

You will receive targeted therapy as part of your routine care or another trial. After about four weeks, you will have a whole body scan to check for changes in radioactive iodine uptake.

Compensation

Not stated in the trial record.

Follow-up

The study will measure the proportion of patients with increased tumor RAI-avidity for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.